The podcast features White House correspondent Deepa Shivaram, political correspondent Danielle Kurtzleben, and health policy correspondent Selena Simmons-Duffin discussing the Supreme Court case on mifepristone. Justices seem skeptical of arguments to restrict access with implications beyond abortion. They delve into the legal battle, conservative arguments for drug legalization, and the dual usage of the medication for miscarriage treatment and abortion, highlighting reproductive care and legal battles.
SCOTUS is skeptical of restricting access to mifepristone, with implications beyond abortion.
Legal battles over Mifepristone could have lasting impacts on abortion laws and patient care.
Deep dives
Supreme Court Case on Mifepristone Accessibility
The Supreme Court heard arguments about the accessibility of Mifepristone used in medication abortions. The case started in 2022 after Roe v. Wade was overturned. The Alliance for Hippocratic Medicine, an anti-abortion group, sued the FDA, challenging the drug's approval process and increased accessibility since 2016. The case questions the rights of the group to sue the FDA and the FDA's decisions on Mifepristone accessibility.
Medical and Business Perspectives on Mifepristone Accessibility
Pharmaceutical companies argue against limiting Mifepristone accessibility, citing potential harm to investments and drug development. The medical community highlights the drug's importance in reproductive care and miscarriage treatment. Legal implications and the historical context of the Comstock Act regarding abortion restrictions raise concerns about broader impacts beyond this case.
Implications and Future Proceedings of the Case
The potential outcomes of the Supreme Court ruling on Mifepristone access involve critical repercussions for abortion laws and patient care. The case may not conclude with the current arguments, as states with anti-abortion laws could intervene with new plaintiffs. The lasting impact of efforts to restrict abortion drugs, as outlined in Project 2025, signals ongoing challenges in abortion access and regulations.
The Supreme Court heard a case this week about mifepristone, a drug used in medication abortions. Anti-abortion plaintiffs are suing the Food & Drug Administration, hoping to restrict access to the drug. But, justices seem skeptical of their arguments, and limits on use of the drug could have long-reaching implications beyond abortion.
This podcast: White House correspondent Deepa Shivaram, political correspondent Danielle Kurtzleben, and health policy correspondent Selena Simmons-Duffin.
This podcast was produced by Jeongyoon Han & Kelli Wessinger, and edited by Casey Morell. Our executive producer is Muthoni Muturi.
Listen to every episode of the NPR Politics Podcast sponsor-free, unlock access to bonus episodes with more from the NPR Politics team, and support public media when you sign up for The NPR Politics Podcast+ at plus.npr.org/politics.